Patents by Inventor Xiyong YU

Xiyong YU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12220461
    Abstract: A polypeptide-coupled small molecule compound and its antiviral applications are provided. The polypeptide-coupled small molecule compound is obtained by linking a polypeptide with a sequence X?nLXGG and a small molecule compound capable of inhibiting activity of papain-like protease (PLpro) of coronavirus through a chemical bond. The polypeptide with the sequence X?nLXGG is a polypeptide with a sequence LXGG at its carboxyl terminal, X and X? are independently any amino acid, and n is an integer between 1-50. The structure of the small molecule compound capable of inhibiting the activity of PLpro contains an amino group or a hydroxyl group. The polypeptide-coupled small molecule compound can inhibit the PLpro of SARS-CoV-2 in a targeted manner, thereby inhibiting the polyprotein cleavage of coronavirus in the host, and achieving the purpose of inhibiting the replication of coronavirus in the host. It has the advantages of synergistic inhibition, low cytotoxicity and favorable solubility.
    Type: Grant
    Filed: May 17, 2024
    Date of Patent: February 11, 2025
    Assignee: Guangzhou Medical University
    Inventors: Xiyong Yu, Ao Shen, Hua Tao, Lixin Zhao, Nanshan Zhong, Qiulian Zhu
  • Publication number: 20250032485
    Abstract: The present disclosure provides methods, compounds and compositions that are relevant to DNA-repair and DNA-repair proteins such as tyrosyl-DNA phosphodiesterase 1 (TDP1) and type I topoisomerase (TOP1).
    Type: Application
    Filed: July 11, 2024
    Publication date: January 30, 2025
    Inventors: XIYONG YU, AO SHEN, LIXIN ZHAO, HUA TAO, NANSHAN ZHONG
  • Publication number: 20240392253
    Abstract: A composition for induction of a pluripotent stem cell including a microRNA and a combination of small-molecule compounds. The microRNA includes one of the miR-290 family members, or a microRNA sequence having at least 90% identity with a sequence of one of the miR-290 family members. The combination of small-molecule compounds includes a histone deacetylase inhibitor, a mitogen-activated extracellular signal-regulated kinase inhibitor, a glycogen synthase kinase-3 inhibitor, a transforming growth factor beta receptor 1 (TGF-?R1) inhibitor, and an inhibitor of histone demethylase.
    Type: Application
    Filed: August 5, 2024
    Publication date: November 28, 2024
    Inventors: Xiyong YU, Jialiang LIANG, Yigang WANG
  • Publication number: 20240382604
    Abstract: A polypeptide-coupled small molecule compound and its antiviral applications are provided. The polypeptide-coupled small molecule compound is obtained by linking a polypeptide with a sequence X?nLXGG and a small molecule compound capable of inhibiting activity of papain-like protease (PLpro) of coronavirus through a chemical bond. The polypeptide with the sequence X?nLXGG is a polypeptide with a sequence LXGG at its carboxyl terminal, X and X? are independently any amino acid, and n is an integer between 1-50. The structure of the small molecule compound capable of inhibiting the activity of PLpro contains an amino group or a hydroxyl group. The polypeptide-coupled small molecule compound can inhibit the PLpro of SARS-CoV-2 in a targeted manner, thereby inhibiting the polyprotein cleavage of coronavirus in the host, and achieving the purpose of inhibiting the replication of coronavirus in the host. It has the advantages of synergistic inhibition, low cytotoxicity and favorable solubility.
    Type: Application
    Filed: May 17, 2024
    Publication date: November 21, 2024
    Inventors: Xiyong Yu, Ao Shen, Hua Tao, Lixin Zhao, Nanshan Zhong, Qiulian Zhu
  • Publication number: 20210095259
    Abstract: A composition for induction of a pluripotent stem cell includes a microRNA and a combination of small-molecule compounds. The combination of small-molecule compounds includes a histone deacetylase inhibitor, a mitogen-activated extracellular signal-regulated kinase inhibitor, a glycogen synthase kinase-3 inhibitor, a transforming growth factor beta receptor 1 (TGF-?R1) inhibitor, an inhibitor of histone demethylase.
    Type: Application
    Filed: December 10, 2020
    Publication date: April 1, 2021
    Inventors: Xiyong YU, Jialiang LIANG, Yigang WANG